Beginner's Mind
Blueprints for Builders and Investors
Hosted by Christian Soschner
From pre-seed to post-IPO, every company—especially in deep tech, biotech, AI, and climate tech—lives or dies by the frameworks it follows.
On Beginner’s Mind, Christian Soschner uncovers the leadership principles behind the world’s most impactful companies—through deep-dive interviews, strategic book reviews, and patterns drawn from history’s greatest business, military, and political minds.
With over 200 interviews, panels, and livestreams, the show ranks in the Top 10% globally—and is recognized as the #1 deep tech podcast.
With 35+ years across M&A, company building, board roles, business schools, ultrarunning, and martial arts, Christian brings a rare lens:
What it really takes to turn breakthrough science into business—how to grow it, lead it, and shape the world around it.
🎙 Expect each episode to deliver:
- Founder & Investor Blueprints: How breakthrough technologies scale from lab to IPO
- Historical & Biographical Frameworks: Timeless playbooks from the world's great builders
- Leadership & Communication Mastery: Tools to inspire, persuade, and lead at scale
Whether you're building the next biotech success, investing in AI, or leading a climate tech company through hypergrowth—this podcast gives you the edge.
Listen in. Apply what matters. Build companies that last.
📬 Join the newsletter & community: https://lsg2g.substack.com/
Beginner's Mind
#34: Sascha Bucher - Deal Structuring With the Pharma Industry - From the Investors Perspective
Drug Development is a challenging process. It needs profound basic research, translating scientific results into products and moving them towards the market.
Making things more challenging deal structuring is also a b2b business, which means selling products to the pharma industry that completes the product development and brings therapeutics to patients.
How does structuring deals with the pharma industry really work to sign one of those multi-billion dollar contracts?
Sascha Bucher is a Venture Capital expert with tremendous experience in deal structuring with the pharmaceutical industry.
In his career at renowned venture funds and companies like Roivant Sciences, Roche, or UBS, he completed transactions worth more than 10 billion dollars.
To give life science entrepreneurs access to the expertise, network, and funding, he and his team are in the process of founding Forty51 Ventures - a novel venture fund dedicated to closing the Life Science Valley of Death in Central Europe.
Join our conversation and learn more about how to negotiate with the pharmaceutical industry.
Gain more insights into VCs' daily business life with a particular focus on building relationships with BD, R&D, and C-suite executives in the industry.
Link to the Video of the Recording:
YouTube
Speaker:
Astrid Woollard
Christian Soschner
Sascha Bucher
Organizations:
CS Life Science Invest
Forty51 Ventures
Scytale Ventures
Join the Podcast Newsletter: Link
